Zobrazeno 1 - 7
of 7
pro vyhledávání: '"James E. Herndon, II"'
Autor:
David J. Carpenter, MD, Andrew T. Fairchild, MD, Justus D. Adamson, PhD, Peter E. Fecci, MD, PhD, John H. Sampson, MD, PhD, James E. Herndon, II, PhD, Jordan A. Torok, MD, Trey C. Mullikin, MD, Grace J. Kim, MD, PhD, Zachary J. Reitman, MD, PhD, John P. Kirkpatrick, MD, PhD, Scott R. Floyd, MD, PhD
Publikováno v:
Advances in Radiation Oncology, Vol 8, Iss 2, Pp 101166- (2023)
Purpose: Hypofractionated stereotactic radiosurgery (HF-SRS) with or without surgical resection is potentially a preferred treatment for larger or symptomatic brain metastases (BMs). Herein, we report clinical outcomes and predictive factors followin
Externí odkaz:
https://doaj.org/article/1cb1e0491df74d279463abda04494634
Autor:
Collin L. Kent, MD, Yvonne M. Mowery, MD, PhD, Olayode Babatunde, MD, Ato O. Wright, MD, Ian Barak, MS, Frances McSherry, MA, James E. Herndon, II, PhD, Allan H. Friedman, MD, Ali Zomorodi, MD, Katherine Peters, MD, PhD, Annick Desjardins, MD, Henry Friedman, MD, William Sperduto, MBS, John P. Kirkpatrick, MD, PhD
Publikováno v:
Advances in Radiation Oncology, Vol 7, Iss 3, Pp 100878- (2022)
Purpose: Atypical (World Health Organization [WHO] grade 2) and malignant (WHO grade 3) meningiomas have high rates of local recurrence, and questions remain about the role of adjuvant radiation therapy (RT) for patients with WHO grade 2 disease. The
Externí odkaz:
https://doaj.org/article/109b243dcbdf431489d044ba13f65cea
Autor:
Anastasie M. Dunn-Pirio, Sarah Woodring, Eric Lipp, James E. Herndon, II, Patrick Healy, Mallika Weant, Dina Randazzo, Annick Desjardins, Henry S. Friedman, Katherine B. Peters
Publikováno v:
Epilepsy and Behavior Case Reports, Vol 10, Iss , Pp 114-117 (2018)
Glioma-associated epilepsy is associated with excessive glutamate signaling. We hypothesized that perampanel, an amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptor antagonist, would treat glioma-related epilepsy. We con
Externí odkaz:
https://doaj.org/article/9b558df933e54c89a08d34abd41958c0
Autor:
Jessica M. Scott, Samantha M. Thomas, James E. Herndon II, Pamela S. Douglas, Anthony F. Yu, Valerie Rusch, James Huang, Catherine Capaci, Jenna N. Harrison, Kurtis J. Stoeckel, Tormod Nilsen, Elisabeth Edvardsen, Meghan G. Michalski, Neil D. Eves, Lee W. Jones
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 12, Iss 6, Pp 1456-1465 (2021)
Abstract Background Poor cardiorespiratory fitness (CRF) is a cardinal feature of post‐treatment primary lung cancer. The most effective exercise therapy regimen to improve CRF has not been determined. Methods In this parallel‐group factorial ran
Externí odkaz:
https://doaj.org/article/fafd36ea1c7d42cda5e4c1740588d1fc
Autor:
Laura Noteware, Gloria Broadwater, Nicole Dalal, Laura Alder, James E. Herndon II, Scott Floyd, William Giles, Amanda E. D. Van Swearingen, Carey K. Anders, Sarah Sammons
Publikováno v:
Breast Cancer Research and Treatment. 197:425-434
Current systemic therapy guidelines for patients with HER2 + breast cancer brain metastases (BCBrM) diverge based on the status of extracranial disease (ECD). An in-depth understanding of the impact of ECD on outcomes in HER2 + BCBrM has never been p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef23fb8edd95e74d95de8f199126b754
https://doi.org/10.1007/s10549-022-06799-7
https://doi.org/10.1007/s10549-022-06799-7
Autor:
Annick Desjardins, Vidya Chandramohan, Daniel Landi, Katherine B Peters, Margaret Johnson, Mustafa Khasraw, Justin Low, Stevie Threatt, Chevelle Bullock, James E Herndon II, Eric S Lipp, John Sampson, Allan Friedman, Henry S Friedman, David Ashley, David Knorr, Jeffrey Ravetch, Darell Bigner
Publikováno v:
Neuro-Oncology. 24:vii65-vii65
BACKGROUND D2C7-IT, a novel immunotoxin-based cytotoxic therapy, targets epidermal growth factor receptor (EGFR) and mutant EGFR variant III. In preclinical studies, D2C7-IT kills tumor cells and prolongs survival, but is unable to generate cures in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::514c72b5f23b2e4bbeefb01eae2e984a
https://doi.org/10.1093/neuonc/noac209.255
https://doi.org/10.1093/neuonc/noac209.255
Autor:
Emil Lou, Katherine B. Peters, Ashley L. Sumrall, Annick Desjardins, David A. Reardon, Eric S. Lipp, James E. Herndon II, April Coan, Leighann Bailey, Scott Turner, Henry S. Friedman, James J. Vredenburgh
Publikováno v:
Cancer Medicine, Vol 2, Iss 2, Pp 185-195 (2013)
Abstract Patients with unresectable glioblastomas have a poor prognosis, with median survival of 6–10 months. We conducted a phase II trial of upfront 5‐day temozolomide (TMZ) and bevacizumab (BV) in patients with newly diagnosed unresectable or
Externí odkaz:
https://doaj.org/article/878b6c7f1e0040d09fdb3980bb1eb49e